H.C. Wainwright lifts target for Kodiak Sciences stock to USD 126.00

Published on 10/24/2026 at 21:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kodiak Sciences launched a USD 350.0 million offering on October 24, 2026. Kodiak Sciences stock costs EUR 78.22 on October 24, 2026.

Analyst target and funding

H.C. Wainwright set a USD 126.00 target on October 12, 2026.
Kodiak Sciences launched a USD 350.0 million equity offering on October 24, 2026.
KOD stock costs EUR 78.22 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.
Third-quarter results are scheduled for November 12, 2026.

KOD, US50015M1099, Illustration mit AI erstellt.

H.C. Wainwright raised its target for Kodiak Sciences stock from USD 96.00 to USD 126.00 on October 12, 2026, according to Futubull. Against the USD 87.63 Nasdaq price on October 23, 2026, the new target lies 43.79 percent above the price. The stock was trading at EUR 78.22 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.

Fresh capital changes the picture

Kodiak Sciences had launched a USD 350.0 million at-the-market equity offering on October 24, 2026, according to Simply Wall St. The financing gives the clinical-stage biotechnology company additional funding capacity while increasing the importance of execution and dilution for shareholders.

Retina pipeline remains central

In its September 2026 corporate profile, Kodiak Sciences described three late-stage clinical programs and identified Zenkuda, also known as tarcocimab, as its lead investigational medicine. The company said Zenkuda had completed four Phase 3 pivotal studies, while the DAYBREAK study had completed enrollment. These statements come from the company's Kodiak Sciences investor-relations page.

Stock remains below its yearly high

The Nasdaq price of USD 87.63 on October 23, 2026 stood 15.74 percent below the 52-week high of USD 104.00 and above the 52-week low of USD 15.83. Kodiak Sciences had a market capitalization of USD 5.5 billion on that date. Simply Wall St also reported a 236.78 percent year-to-date gain on October 24, 2026.

Results date sets the next marker

Third-quarter 2026 results are scheduled for November 12, 2026, according to Barron's. The report will give investors a new financial checkpoint after the second-quarter net loss reached USD 65.64 million and cash stood at USD 125.90 million for the period ended June 30, 2026.

Euro quote for German investors

Kodiak Sciences is a Nasdaq-listed biotechnology company focused on retinal diseases. Its current euro quote stood at EUR 78.22 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Kodiak Sciences stock.